12.08.25 -- STREAM Edition: Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.

Leveraging decades of expertise, analytical capabilities, and regulatory knowledge, we deliver phase-appropriate solutions that streamline development, reduce risk, and accelerate timelines.

If you are in the process of developing a complex or sensitive injectable drug, learn about containment solutions to mitigate your risks and help you get your drug to the patient faster.

Develop lower-risk conjugation strategies by incorporating the critical insights we highlight in our review of semi-synthetic versus synthetic linker–payloads and their respective advantages and limitations.

Experts share strategies to accelerate ADC development, including optimizing supply chains, seamless scale-up to GMP manufacturing, and leveraging process analytical technology.

On this week's Business Of Biotech episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, the impact of China's rising biotech sector, and the keys to successful collaboration.

Explore the formulation and manufacturing considerations for amorphous solid dispersions (ASDs), with a focus on hot melt extrusion (HME) as a scalable and cost-effective technology option.

Our dedicated team of in-house design specialists deliver insightful packaging design and practical knowledge to deliver differentiated and cost-effective packaging solutions.